


Contents lists available at ScienceDirect

Virology

journal homepage: www.elsevier.com/locate/yviro

Review

Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies

Sebastien E. Emonet¹, Shuzo Urata¹, Juan C. de la Torre^{*,1}

Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

ARTICLE INFO

Article history:

Received 10 January 2011

Accepted 12 January 2011

Available online 15 February 2011

Keywords:

Arenavirus

Reverse genetics

Human pathogenic arenaviruses

ABSTRACT

Several arenaviruses, chiefly Lassa virus, cause hemorrhagic fever disease in humans and pose a significant public health problem in their endemic regions. On the other hand the prototypic arenavirus LCMV is a superb workhorse for the investigation of virus–host interactions and associated disease. The development of novel antiviral strategies to combat pathogenic arenaviruses would be facilitated by a detailed understanding of the arenavirus molecular and cell biology. To this end, the development of reverse genetic systems for several arenaviruses has provided investigators with novel and powerful approaches to dissect the functions of arenavirus proteins and their interactions with host factors required to complete each of the steps of the virus life cycle, as well as to cause disease.

© 2011 Elsevier Inc. All rights reserved.

Contents

Introduction	416
Arenaviruses and their impact in human health and microbial science	417
Arenavirus genome organization and proteins	417
Arenavirus life cycle	418
Reverse genetics and their implications for the investigation of arenavirus molecular and cell biology	418
Arenavirus MG systems	418
Generation of recombinant arenaviruses	419
Harnessing arenavirus reverse genetics for the development of novel strategies to combat human pathogenic arenaviruses.	421
Novel targeting strategies	421
Targeting the biosynthetic processes, RNA replication and gene transcription, directed by the arenavirus polymerase complex	422
Targeting the S1P mediated processing of arenavirus GPC	422
Targeting virus budding	422
Novel vaccine strategies	422
Concluding remarks and perspectives	423
Acknowledgments	423
References	423

Introduction

Arenaviruses cause chronic infections of rodents with a worldwide distribution (Buchmeier et al., 2007). Human can be infected through mucosal exposure to aerosols, or by direct contact of abrade skin with infectious material, derived from infected rodents. Several arena-

viruses cause hemorrhagic fever (HF) disease in humans and pose a great public health concern within the virus endemic regions (Buchmeier et al., 2007). On the other hand, the prototypic arenavirus LCMV is a superb workhorse for the investigation of virus–host interactions including mechanisms of virus control and clearance by the host immune defenses, as well as viral counteracting measures leading to chronic infection and associated disease (Oldstone, 2002; Zinkernagel, 2002). This review will focus on recent developments on arenavirus reverse genetics and their implications for a better understanding of the arenavirus molecular and cell biology, as well as mechanisms underlying arenavirus–host interactions and

* Corresponding author. Fax: +1 858 784 9981.

E-mail address: juant@scripps.edu (J.C. de la Torre).

¹ All authors equally contributed to the preparation of this minireview.

associated disease and the development of novel antiviral drugs and vaccine strategies to combat pathogenic arenaviruses.

Arenaviruses and their impact in human health and microbial science

The Old World (OW) Lassa virus (LASV) and several New World (NW) arenaviruses cause HF disease in humans (Buchmeier et al., 2007). Thus, LASV is estimated to infect several hundred thousand individuals yearly in its endemic regions of West Africa, resulting in a high number of Lassa fever (LF) cases associated with high morbidity and significant mortality. Likewise, the NW arenavirus Junin virus (JUNV) causes Argentine HF, a severe illness with hemorrhagic and neurological manifestations and a case fatality of 15–30%, whereas the NW Machupo (MACV) and Guarito (GTOV) arenaviruses emerged as causative agents of HF in Bolivia and Venezuela, respectively (Peters, 2002). Notably, increased traveling to and from endemic regions has led to the importation of LF into non-endemic metropolitan areas around the globe (Isaacson, 2001). Moreover, compelling evidence indicates that the globally distributed prototypic arenavirus LCMV is a neglected human pathogen of clinical significance, especially in cases of congenital infection leading to hydrocephalus, mental retardation and chorioretinitis (Barton et al., 2002). In addition, LCMV poses special threat to immuno-compromised individuals, as illustrated by recent cases of transplant-associated infections by LCMV with a fatal outcome in the USA (Fischer et al., 2006) and Australia (Palacios et al., 2008).

Studies on the prototypic arenavirus LCMV have led to major advances in virology and immunology that apply universally to other microbial infections and viral infections of humans, including virus-induced immunopathological disease, MHC restriction and mechanisms of virus induced immunosuppression (Oldstone, 2002; Zinkernagel, 2002). The outcome of LCMV infection of its natural host, the mouse, varies dramatically depending on the strain, age, immunocompetence and genetic background of the host, as well as the route of infection, and the strain and dose of infecting virus (Oldstone, 2002; Zinkernagel, 2002). This provides investigators with a unique model system to investigate parameters that critically influence many aspects of virus–host interaction including the heterogeneity of phenotypic manifestations often associated with infection by the same virus.

Arenavirus genome organization and proteins

Arenaviruses are enveloped viruses with a bi-segmented negative strand (NS) RNA genome and a life cycle restricted to the cell cytoplasm. Virions are pleomorphic but often spherical and covered with surface glycoprotein spikes. Both the large, L (ca 7.3 kb) and small, S (ca 3.5 kb) genome RNA species use an ambisense coding strategy to direct the synthesis of two polypeptides in opposite orientation, separated by a non-coding intergenic region (IGR) with a predicted folding of a stable hairpin structure (Buchmeier et al., 2007) (Fig. 1). The S RNA encodes the viral glycoprotein precursor, GPC, (ca 75 kDa) and the nucleoprotein, NP, (ca 63 kDa), whereas the L RNA encodes the viral RNA dependent RNA polymerase (RdRp, or L polymerase) (ca 200 kDa), and a small (ca 11 kDa) RING finger protein Z that is functionally the counterpart of the matrix (M) protein found in many enveloped NS RNA viruses.

Arenaviruses exhibit high degree of sequence conservation at the genome 3'-termini (17 out of 19 nt are identical) and, as with other NS RNA viruses, arenavirus genome termini exhibit terminal complementarity with the 5'- and 3'-ends of both L and S genome segments predicted to form panhandle structures. For several arenaviruses, an additional non-templated G residue has been detected on the 5' end of their genome RNAs. There are significant differences in sequence and predicted folded structure between the S and L IGR, but among isolates and strains of the same arenavirus species the S, as well as L, IGR sequences are highly conserved.

The NP, the most abundant viral polypeptide both in infected cells and virions, is the main structural element of the viral RNP and plays an essential role in viral RNA synthesis. Recent evidence indicates that NP exhibits also a type I interferon (IFN-I) counteracting activity (Martinez-Sobrido et al., 2009, 2007, 2006). This anti-IFN activity was mapped to the C-terminus of NP. The recently determined crystal structure of LASV NP at 1.80 Å resolution identified distinct N- and C-terminal domains (Qi et al., 2010). The N-terminal domain has a potential cap-binding activity that could provide the host-derived primers to initiate transcription by the virus polymerase (Qi et al., 2010). In contrast, the C-terminal domain has a folding that mimics that of the DEDDH family of 3'-5' exoribonucleases like the one associated with SARS Corona virus nsp14 protein (Eckerle et al., 2010). Functional studies confirmed the 3'-5' exoribonuclease activity of LASV NP, which was proposed to be critical for the anti-




Fig. 1. Arenavirus genome organization and virion structure. Arenaviruses are enveloped viruses with a bi-segmented negative strand RNA genome. Each genome segment uses an ambi-sense coding strategy to direct the synthesis of two viral polypeptides. The S (ca 3.5 kb) segment encodes for the viral nucleoprotein (NP) and glycoprotein precursor (GPC). GPC is posttranslational processed into GP1 and GP2. The L (ca 7.3 kb) segment encodes for the viral RNA dependent RNA polymerase (L) and a small RING finger protein (Z) that is functionally the arenavirus counterpart of the matrix (M) protein found in many enveloped negative strand RNA viruses.

IFN activity of NP but dispensable for the role of NP on replication and transcription of the viral genome (Qi et al., 2010). This assertion, however, is difficult to reconcile with the lack of anti-IFN activity associated with the NP of TACV (Martinez-Sobrido et al., 2007) and the finding that an LCMV with a mutant NP lacking the 3′–5′ exonuclease had a large decrease in fitness during its replication in IFN-deficient Vero cells (Martinez-Sobrido et al., 2009). The viral glycoprotein precursor GPC is post-translationally proteolytically processed by the S1P cellular protease to yield the two mature virion glycoproteins GP-1 (40–46 kDa) and GP-2 (35 kDa) (Beyer et al., 2003; Lenz et al., 2001; Pinschewer et al., 2003b). GPC contains a 58-amino-acid signal peptide (SSP) that is expressed as a stable polypeptide in infected cells and it remains associated to the GP complex (GPCx). This SSP has been implicated in different aspects of the trafficking and function of the viral envelope glycoproteins (Saunders et al., 2007; York and Nunberg, 2006; York et al., 2004). GP-1 mediates virus interaction with host cell surface receptors and is located at the top of the spike, away from the membrane, and is held in place by ionic interactions with the N-terminus of the transmembrane GP-2. The arenavirus RING finger protein Z is a structural component of the virion that has no homologue among other known NS RNA viruses. In LCMV-infected cells Z has been shown to interact with several cellular proteins including the promyelocytic leukemia (PML) protein and the eukaryote translation initiation factor 4E (eIF4E), which have been proposed to contribute to the noncytolytic nature of LCMV infection and repression of cap-dependent translation, respectively (Borden et al., 1998a, 1998b; Campbell Dwyer et al., 2000; Djavani et al., 2001; Volpon et al., 2010). Z has been shown to be the arenavirus counterpart of the M protein found in many other NS enveloped RNA viruses that plays a critical role in assembly and cell release of mature infectious virions (Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006).

The arenavirus L protein has the characteristic sequence motifs conserved among the RdRp (L proteins), of negative strand (NS) RNA viruses (Poch et al., 1989). Detailed sequence analysis and secondary structure predictions done with the LASV L polymerase identified several regions of strong alpha-helical content and a putative coiled-coil domain at the N-terminus (Vieth et al., 2004). Subsequent bioinformatic analysis together with biochemical and MG-based functional studies have shown that LASV L protein is likely organized into three distinct structural domains and that at specific amino acid positions LASV L can be split into an N- and C-parts that are able to functionally trans-complement each other (Brunotte et al., 2011). Notably, the recent electron microscopy characterization of a functional MACV L protein has revealed a core ring-domain decorated by appendages, which may reflect a modular organization of the arenavirus polymerase (Kranzusch et al., 2010).

Arenavirus life cycle

Consistent with a broad host range and cell type tropism, a highly conserved and widely expressed cell surface protein, alpha-dystroglycan (αDG) has been identified as a main receptor for LCMV, LASV and several other arenaviruses (Cao et al., 1998; Kunz et al., 2002). However, many arenaviruses appear to use an alternative receptor (Kunz et al., 2004), and human transferrin receptor 1 was identified as a cellular receptor used for entry of NW HF arenaviruses JUNV and MACV (Radoshitzky et al., 2007). Upon receptor binding, arenavirus virions are internalized by uncoated vesicles and released into the cytoplasm by a pH-dependent membrane fusion step that is mediated by GP-2 (Eschli et al., 2006; Gallaher et al., 2001). The fusion between viral and cellular membranes releases the viral RNP into the cytoplasm, which is ensued by the onset of viral RNA synthesis. LCMV mRNAs have 4–5 non-templated nt and a cap structure at their 5′-ends, which are likely obtained from cellular mRNAs via cap-snatching mechanisms whose details remain to be determined. A

recently described endonuclease activity associated with the arenavirus L polymerase could play a critical role in this process (Morin et al., 2010). Transcription termination of subgenomic non-polyadenylated viral mRNAs were mapped to multiple sites within the distal side of the IGR (Meyer and Southern, 1994; Tortorici et al., 2001), which suggested that the IGR acts as a bona fide transcription termination signal for the virus polymerase. The NP and L coding regions are transcribed into a genomic complementary mRNA, whereas the GPC and Z coding regions are not translated directly from genomic RNA, but rather from genomic sense mRNAs that are transcribed using as templates the corresponding antigenome RNA species, which also function as replicative intermediates (Fig. 2).

Assembly and cell release of infectious arenavirus progeny require both Z and GPC, as well as the correct processing by the cellular site 1 protease (S1P) of GPC into GP1 and GP2 (Kunz et al., 2003; Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006).

Reverse genetics and their implications for the investigation of arenavirus molecular and cell biology

The generation of an infectious RNA virus from cloned cDNA, referred to as reverse genetics, was first reported more than 20 years ago for the bacteriophage Q β (Taniguchi et al., 1978), and shortly after a similar approach was reported for the generation of poliovirus (Racaniello and Baltimore, 1981). In contrast to positive-stranded RNA viruses, like bacteriophage Q β , deproteinized genomic and antigenomic RNAs of negative strand (NS) RNA viruses, like LCMV, cannot function as mRNAs and are not infectious. This reflects the fact that the template of the polymerases of NS RNA viruses is exclusively a nucleocapsid consisting of the genomic RNA tightly encapsidated by the NP, which associated with the virus polymerase proteins forms a ribonucleoprotein (RNP) complex. Thus, generation of biologically active synthetic NS viruses from cDNA requires trans complementation by all viral proteins involved in virus replication and transcription. These considerations hindered the application of recombinant DNA technology to the genetic analysis of these viruses. However, following the pioneering work of Palese's group (Luytjes et al., 1989), significant progress has been made in this area and for all NS RNA viruses, short model genomes (aka minigenomes (MG)) could be encapsidated and expressed by plasmid-encoded proteins. Moreover, it has become possible to rescue infectious virus entirely from cloned cDNAs for members of all families of NS RNA viruses (Kawaoka, 2004).

The use of reverse genetic approaches has revolutionized the analysis of cis-acting sequences and trans-acting proteins required for virus replication, transcription, maturation and budding. In addition, the possibility to generate predetermined specific mutations within the virus genome and analyze their phenotypic expression in vivo in the context of the virus natural infection is contributing very significantly to the elucidation of the molecular mechanisms underlying virus–host interactions at the cellular and molecular levels, which has provided investigators with novel and powerful approaches for the investigation of viral pathogenesis. In addition, these developments have also paved the way for engineering these viruses for vaccine and gene therapy purposes (Subbarao and Katz, 2004; von Messling and Cattaneo, 2004).

Arenavirus MG systems

The first arenavirus MG rescue system was developed for LCMV (Lee et al., 2000). Subsequently MG systems were developed for LASV (Hass et al., 2004) and the NW arenaviruses PICV (Lan et al., 2009), TACV (Lopez et al., 2001), and JUNV (Albarino et al., 2009). Results derived from MG-based assays identified NP and L as the minimal viral trans-acting factors required for efficient RNA synthesis mediated by the virus polymerase (Hass et al., 2004; Lee et al., 2000; Lopez et al., 2001). For LCMV both genetic and biochemical




Fig. 2. Arenavirus RNA replication and gene expression. Once the virus RNP is delivered into the cytoplasm of the infected cell, the polymerase associated with the virus RNP initiates transcription from the genome promoter located at the genome 3'-end. Primary transcription results in synthesis of NP and L mRNA from the S and L, respectively, segments. Subsequently the virus polymerase can adopt a replicase mode and moves across the IGR to generate a copy of the full-length antigenome RNA (agRNA). This agRNA will serve as template for the synthesis of the GP (agS) and Z (agL) mRNAs. The agRNA species serve also as templates for the amplification of the corresponding genome RNA species.

evidence indicated that oligomerization of L is required for the activity of the arenavirus polymerase (Sanchez and de la Torre, 2005). Consistent with this finding biochemical and MG-based functional studies have shown that LASV L protein contains both N- and C-termini sites that mediate L–L interaction (Brunotte et al., 2011). The use of MG-based assays facilitated mutation–function studies involving conserved acidic and basic amino acid residues within the N- and C-termini of LASV L protein uncovered several residues within the N-terminus of L that played a critical role in synthesis of viral mRNA but not in RNA replication (Hass et al., 2008; Lelke et al., 2010). The recent publication of an 2.13 Å resolution crystal structure and functional characterization of the N-terminal 196 residues (NL1) of the LCMV L protein uncovered an endonuclease functional domain similar to the one found in the N-terminus of the influenza virus PA protein (Morin et al., 2010), and MG-based assays shown the endonuclease activity of NL1 to be critical for arenavirus transcription (Morin et al., 2010).

Mutation–function analysis of the genome 5'- and 3'-termini using the LCMV and LASV MG-based assays indicated that the activity of the arenavirus genomic promoter requires both sequence specificity within the highly conserved 3'-terminal 19 nt of arenavirus genomes, and the integrity of the predicted panhandle structure formed via sequence complementarity between the 5'- and 3'-termini of viral genome RNAs (Hass et al., 2006; Perez and de la Torre, 2003). These studies revealed that arenavirus RNA replication and transcription are regulated in a coordinated manner. Likewise, MG-based assays provided direct experimental confirmation that the IGR is a bona fide transcription termination signal (Pinschewer et al., 2005), and that intracellular levels of NP do not determine the balance between virus RNA replication and transcription (Pinschewer, Perez, and de la

Torre, 2003), a finding conceptually similar to that reported for the paramyxovirus RSV (Fearnly et al., 1997).

Z was not required for intracellular transcription and replication of a LCMV MG, but rather Z exhibited a dose dependent inhibitory effect on both transcription and replication of LCMV MG (Cornu and de la Torre, 2001, 2002; Cornu et al., 2004). This inhibitory effect of Z has been also reported for TACV (Lopez et al., 2001) and LASV (Hass et al., 2004). For most enveloped viruses, a matrix (M) protein is involved in organizing the virion components prior to assembly. Interestingly, arenaviruses do not have an obvious counterpart of M. However, Z has been shown to be the main driving force of arenavirus budding (Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006), a process mediated by the Z late (L) domain motifs: PTAP and PPPY similar to those known to control budding of several other viruses including HIV and Ebola virus, via interaction with specific host cell proteins (Freed, 2002). Consistent with this observation Z exhibited features characteristic of bona fide budding proteins: 1) ability to bud from cells by itself, and 2) substituted efficiently for other L domain. Targeting of Z to the plasma membrane, the location of arenavirus budding, strictly required its myristoylation (Perez et al., 2004; Strecker et al., 2006). Results derived from cryo-electron microscopy of arenavirus particles (Neuman et al., 2005) were also consistent with the role of Z as a functional M protein.

Generation of recombinant arenaviruses

Generation of infectious virus from cloned cDNAs has been reported for LCMV (Flatz et al., 2006; Sanchez and de la Torre, 2006), PICV (Lan et al., 2009) and JUNV (Albarino et al., 2009; Emonet

et al., 2011). The ability to generate recombinant arenaviruses with predetermined specific mutations and analyze their phenotypic expression in the context of the natural course of infection has opened new opportunities to investigate arenavirus–host interactions that influence a variable infection outcome, ranging from virus control and clearance by the host defenses to long-term chronic infection associated with subclinical disease, and severe acute disease including HF.

The generation of the first recombinant arenavirus via a reverse genetic approach consisted in the replacement of the LCMV GP gene by the one of VSV G (Pinschewer et al., 2003b). This virus, called rLCMV/VSVG, was generated through transfection of cells with a plasmid expressing a recombinant LCMV S RNA segment, where VSV G substituted for LCMV GPC, followed by infection with WT LCMV as helper virus. The supernatant from infected cells contained a mix of WT LCMV and rLCMV/VSVG and selection of rLCMV/VSVG was done via passages in S1P-deficient cells, where the LCMV WT could not produce an infectious progeny. This approach was limited to the generation of rLCMV for the S segment and required a time-consuming selection process. These limitations were overcome by the rescue of infectious LCMV progeny entirely from cloned cDNAs using either a T7 RNA polymerase (RP) (Sanchez and de la Torre, 2006) or pol-I RP (Flatz et al., 2006) system to launch intracellular

synthesis of S and L genome, or antigenome, RNA species that were subsequently replicated and transcribed by the virus polymerase complex reconstituted intracellularly via plasmid-supplied L and NP (Fig. 3). Both systems exhibited similar efficiencies and the same virus rescued by any of the two systems displayed the same phenotypic properties both in cultured cells and in vivo. This successful rescue of LCMV from cloned cDNA was subsequently extended to other strains of LCMV (Chen et al., 2008) and to the NW arenaviruses Pichinde virus (PICV) (Lan et al., 2009) and Junin virus (JUNV) (Albarino et al., 2009). Intriguingly, the rescue of PICV and JUNV using the T7RP-based system did not require plasmid-supplied viral NP and L proteins (Albarino et al., 2009; Lan et al., 2009; Liang et al., 2009), indicating that T7RP-mediated RNA synthesis produced both viral antigenome RNA species that were substrate for encapsidation and replication, and mRNAs that serve as template to produce levels of NP and L sufficiently high to facilitate virus rescue. This phenomenon has been reported for several other negative-sense RNA viruses, including bunyaviruses (Blakqori and Weber, 2005; Lowen et al., 2004), filoviruses (Groseth et al., 2005), and bornaviruses (Schneider et al., 2005). Moreover, for the orthobunyavirus La Crosse virus and arenavirus PICV, the use of plasmid supplied viral trans-acting factors was documented to diminish the efficiency of the system (Blakqori and Weber, 2005; Liang et al., 2009).




Fig. 3. Generation of recombinant arenaviruses via reverse genetics. Cells are transfected with plasmids that direct intracellular synthesis of the L and S genome, or antigenome, RNA species via either T7 RNA polymerase (T7RP) or RNA polymerase I (pol-I), together with pol-II expression plasmids for the viral trans-acting factors L and NP. For rescues using T7RP-mediated intracellular synthesis of L and S RNA species, the addition of a pol-II expression plasmid for T7RP is optional. At 48–72 h post-transfection the virus-containing tissue culture supernatant is collected and used for amplification and purification of the recombinant virus.

Reverse genetic approaches similar to those used to rescue infectious LCMV, PICV and JUNV from cloned cDNAs should be now applicable to other arenaviruses. The T7RP-based system offers the advantage of requiring only transfection of plasmids expressing the viral genome RNAs. However, the T7RP has to be also provided either via transfection or by the use of a cell line stably expressing T7RP. The non-templated G found at the 5'-end of arenavirus genome RNA species (Garcin and Kolakofsky, 1990; Raju et al., 1990) does not pose a problem as truncated T7RP promoters that direct RNA synthesis by T7RP starting with exhibit good levels of transcriptional activity (Sousa and Mukherjee, 2003). The activity of genome promoter present at the 3'-end of the S and L genomic RNAs was found to be dramatically affected by mutations with the 3'-terminal 19 nt (Hass et al., 2006; Perez and de la Torre, 2003). The generation of authentic 3'-end viral genome termini using the T7RP is facilitated by the incorporation of the HDV ribozyme downstream to the T7RP termination sequence (Liang et al., 2009; Sanchez and de la Torre, 2006), but variability in the ribozyme cleavage efficiency could negatively affect the rescue efficiency. T7RP-mediated transcription can trigger the IFN-I response, via RIG-I (Habjan et al., 2008), which could compromise the rescue recombinant viruses with enhanced susceptibility to INF-I.

The RNA pol I is localized in the nucleus of the cell and directs synthesis of the large ribosomal RNA precursor that will be processed into rRNA 5.8S, 28S and 18S (Comai, 2004). The pol I-based system was first used with influenza virus, whose replication occurs in the nucleus of infected cells (Neumann and Kawaoka, 2004), but subsequently it has been used for the rescue of a variety of NS RNA viruses including bunyaviruses, filoviruses and arenaviruses (Flatz et al., 2006; Groseth et al., 2005; Habjan et al., 2008; Ogawa et al., 2007). A limitation of the pol-I system is the species-specific activity of the promoter (Comai, 2004; Neumann and Kawaoka, 2004), which would prevent the use of a given pol-I construct with every cell line of interest. On the other hand, transcription termination of the RNA pol-I occurs very precisely at the pol-I termination signal, which eliminates the need to add any ribozyme between the end of the viral RNA and the pol I terminator. Besides their pros and cons, both T7RP and pol-I systems have been proven to be similar efficient for the rescue of arenaviruses (Sanchez and de la Torre, 2006), and other negative-sense RNA viruses (Habjan et al., 2008).

Another important aspect to consider for a successful arenavirus rescue is the need to confirm the sequence of the 5'- and 3'-termini of the S and L genome RNAs. These cis-acting regulatory sequences play a critical role in the control of RNA synthesis by the virus polymerase, and minimal changes within them would likely prevent virus rescue. Obtaining the correct sequence for the L IGR sequences and a functional clone of the L polymerase are additional key factors when attempting to rescue a given arenavirus for the first time.

The ability to generate recombinant arenaviruses with predetermined specific mutations and analyze their phenotypic expression in the context of the natural course of infection has opened new opportunities to investigate arenavirus–host interactions that influence a variable infection outcome, ranging from virus control and clearance by the host defenses to long-term chronic infection associated with subclinical disease, and severe acute disease including HF. Thus, the use of rLCMV/VSVG uncovered the arenavirus GP as a viral Achilles' heel and provided the foundations for a novel strategy to develop safe and effective live-attenuated arenavirus vaccines (Pinschewer et al., 2003a, 2003b). Likewise, rLCMV/VSVG was very instrumental in facilitating studies aimed at understanding the regulation of CD8+ T cell function within the infected brain (Pinschewer et al., 2010), as well as how viruses can induce organ-specific immune disease in the absence of molecular mimicry and without disruption of self tolerance (Merkler et al., 2006). Other engineered rLCM viruses have been used to study LASV cell entry pathway (Rojek and Kunz, 2008) and the role of NP in the inhibition of

induction of IFN-I by LCMV (Martinez-Sobrido et al., 2009). Likewise, studies aimed at examining the critical role played by the S1P-mediated processing of arenavirus GPC in the virus life cycle were aided by the use of recombinant viruses where the S1P cleavage site within GPC was replaced by a canonical furin cleavage site (Albarino et al., 2009; Rojek et al., 2010; Urata et al., 2011). The rescue of attenuated and virulent forms of PICV (Lan et al., 2009; Liang et al., 2009), or the Docil and Aggressive strains of LCMV (Chen et al., 2008) have allowed for the identification of specific genetic determinants virus virulence. Despite the facile generation of these recombinant arenaviruses, the ability to rescue arenaviruses expressing additional genes of interest posed unexpected difficulties. Approaches successfully employed with other NS RNA viruses including the use of an internal ribosome entry site (IRES), or of the picornavirus self-cleaving 2A protease, did not work when applied to LCMV. This problem was overcome by the generation of tri-segmented rLCMV (r3LCMV) containing 1L and 2S segments. Each of the two S segments was altered to replace one of the two viral ORF, GPC or NP, by a gene of interest (GOI) (Emonet et al., 2009). The rationale behind this approach was that the physical separation of GP and NP into two different S segments would represent a strong selective pressure to select and maintain a virus capable of packaging 1L and 2S segments. A variety of r3LCMV have been rescued that express one or two additional GOI. Depending on the GOI expressed (protein function, size of the gene), these r3LCMV showed little or no attenuation in cultured cells and they exhibited long-term genetic stability as reflected by unaltered expression levels during serial virus passages of the GOI incorporated into the S segment. The use of r3LCMV expressing appropriate reporter genes should facilitate the development of chemical screens to identify antiviral drugs, as well as siRNA-based genetic screens to identify host cell genes contributing to the different steps of the arenavirus life cycle. In contrast, the use of r3LCMV to study virus–host interactions in mice has encountered some limitations due to the observation that even r3LCMV with WT growth properties in cultured cells exhibited an attenuated phenotype in the mouse due to reasons that remain to be determined.

Harnessing arenavirus reverse genetics for the development of novel strategies to combat human pathogenic arenaviruses

Novel targeting strategies

In vitro and in vivo studies have documented the prophylactic and therapeutic value of the nucleoside analogue ribavirin (Rib) against several arenaviruses (Damonte and Coto, 2002). Importantly, Rib reduced both morbidity and mortality in humans associated with LASV infection, and experimentally in MACV and JUNV infections, if given early in the course of clinical disease (Damonte and Coto, 2002). The mechanisms by which Rib exerts its anti-arenaviral action remain poorly understood, but likely involve targeting different steps of the virus life cycle (Parker, 2005). Two important limitations of the use of Rib therapy are the need of intravenous administration for optimal efficacy and significant side effects including anemia and congenital disorders. Several inhibitors of IMP dehydrogenase, the S-adenosyl-homocysteine (SAH) hydrolase, a variety of sulfated polysaccharides, phenothiazines compounds, brassinosteroids and myristic acid have been reported to have anti-arenaviral activity (Damonte and Coto, 2002). However, these compounds displayed only modest and rather non-specific effects associated with significant toxicity. Therefore there is a pressing need for novel effective anti-arenaviral drugs. In this regard, a recent high-throughput screening (HTS) using a virus-induced cytopathic effect (CPE)-based assay identified a potent small molecule inhibitor of TACV and several other NW arenaviruses (Bolken et al., 2006). Likewise, cell-based HTS based on the use of pseudotyped virion particles bearing the GP of highly pathogenic arenaviruses identified several small molecule inhibitors of virus cell

entry mediated by LASV GP (Lee et al., 2008). These findings illustrate how screening of complex chemical libraries using appropriate assays represents a powerful tool to identify candidate antiviral drugs with highly specific activities. Progress in arenavirus reverse genetics is allowing investigators to dissect each of the steps of the virus life cycle to uncover novel targets and develop screens to identify drugs directed against specific steps of the arenavirus life cycle.

Targeting the biosynthetic processes, RNA replication and gene transcription, directed by the arenavirus polymerase complex

Results from mutation–function studies have identified the core of the arenavirus genome promoter and uncover that both sequence specificity and structure are critical for promoter activity. Disruption of the interaction between the arenavirus genome promoter and the virus polymerase complex would interfere with the essential biosynthetic processes of viral transcription and replication, which is expected to have a strong deleterious impact on virus viability. Hence, small molecules that interfere specifically with this interaction could be efficacious antiviral agents.

Effector small molecules targeted at RNA may interfere with RNA functions by a number of mechanisms. They can alter the functional three-dimensional structure of the RNA molecule, so that interaction with proteins is affected. Also, as interface inhibitors, they may directly prevent the formation of competent RNA–protein complexes. The study of small molecule RNA effectors has primarily focused on the aminoglycosides (Hermann, 2000; Hermann and Westhof, 2000; Sucheck et al., 2000; Sucheck and Wong, 2000; Wilson and Li, 2000). The antibiotic activity associated with aminoglycoside targeting of bacterial 16S ribosomal RNA is a well-known success case. The potential of aminoglycosides as antiviral molecules by acting on RNA has been illustrated by their ability to disrupt selectively the HIV-1 Rev-RRE (Wang et al., 1997) and Tat-TAR (Wang et al., 1998) interactions. Similar approaches should be applicable to inhibit the interaction between the arenavirus promoter and polymerase complex. The genome core promoter is highly conserved among all known arenaviruses, and recent studies have defined a motif at positions 2–5 of the 3′ promoter that plays a key role in L polymerase binding (Kranzusch et al., 2010). These findings predict the feasibility of identifying aminoglycoside-based molecules with antiviral activity active against different human pathogenic arenaviruses.

Mutation–function studies on the LCMV and LASV L polymerases using MG-based systems combined with biochemical assays have provided evidence of the requirement of L–L interaction for polymerase activity. This finding has uncovered the possibility of using small molecules to disrupt L–L interaction as a novel strategy to inhibit arenavirus multiplication.

Targeting the S1P mediated processing of arenavirus GPC

Correct processing of arenavirus GPC by the cellular site 1 protease (S1P) is strictly required for production of infectious progeny and cell-to-cell virus propagation, and thereby for both intra- and inter-host virus propagation (Kunz et al., 2003). Intriguingly, studies on LCMV and JUNV infection of cells deficient in S1P indicated that the appearance of viral variants capable of growing independently of S1P-mediated processing of GPC appears to be highly unlikely. These findings strongly support the idea that inhibitors of S1P-mediated processing of GPC would represent promising anti-arenaviral drug candidates (Rojek et al., 2008, 2010). S1P is encoded by the membrane bound transcription-factor protease site 1 gene and is an endoplasmic reticulum (ER)/early Golgi membrane-anchored serine protease (Sakai et al., 1998; Seidah et al., 2006). Despite its broad consensus sequence, S1P exhibits exquisite substrate specificity and is involved in proteolytic processing of a defined set of cellular proteins. The key role of S1P in the regulation of lipid metabolism and cholesterol biosynthesis has raised significant interest in developing specific inhibitors of S1P activity. Several peptide and non-peptide-based S1P

inhibitors have been documented but their lack of cell permeability would pose severe limitations to their use as antiviral drugs. Recently, decanoylated chloromethylketone (CMK)-derivatized peptides containing the RRL recognition sequence of S1P have been shown to act as potent suicide inhibitors of S1P catalytic activity. These drugs cause irreversible inhibition of the catalytic activity of S1P against host cell and pathogen derived targets, which might result in unacceptable levels of cellular toxicity. Recently, the small molecule PF-429242 was reported to be a potent S1P inhibitor both in vitro and in cell-based assay (Hawkins et al., 2008; Hay et al., 2007). In addition, PF-429242 was shown to inhibit efficiently S1P-mediated processing of arenavirus GPC, which correlated with the drug's ability to interfere with propagation of both LCMV and LASV in cultured cells (Urata et al., 2011).

Targeting virus budding

The arenavirus Z protein has features characteristic of a bona fide budding proteins (Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006). For many characterized viral budding proteins, their budding activity requires interaction, via its L domains, with specific host cellular factors including members of the ESCRT machinery within the endosomal/MVB pathway of the cell. In this regard TSG101, a member of the ESCRT-I complex, has been identified as a host cellular protein required for Z-mediated budding. Accordingly, siRNA-mediated knock-down of TSG101 was found to interfere with Z-mediated budding. The use of recombinant arenaviruses expressing appropriate tagged versions of Z should facilitate studies aimed at the identification and characterization of the Z-host cell protein interactions involved in arenavirus budding in the context of the virus natural course of infection. Knowledge from these studies may uncover novel targets and facilitate the development of screening processes to identify small molecules capable of disrupting these interactions and thereby interfering with virus propagation. The ESCRT machinery participates in a variety of processes required for normal cell physiology (Carlton, 2010; Morita et al., 2010) and therefore long-term disruption of the normal function of ESCRT components is likely to result in unacceptable levels of toxicity. However, arenavirus induced HF are acute disease processes, and it is plausible that short term inhibition of ESCRT members to combat an acute HF arenaviral disease may cause only limited toxicity.

Novel vaccine strategies

The JUNV live attenuated Candid #1 strain, derived from the 44th mouse brain passage of prototype XJ strain of JUNV, was found to be attenuated in guinea pigs and preclinical studies supported the safety, immunogenicity and protective efficacy of Candid #1 in both guinea pigs and rhesus macaques (McKee et al., 1992). Moreover, studies involving agricultural workers in the JUNV endemic area have shown Candid #1 to be an effective and safe vaccine in humans (Enria and Barrera Oro, 2002; Maiztegui et al., 1998). Candid #1 was licensed in 2006 for use exclusively in Argentina. Despite its success, there are some limitations associated with the Candid #1 vaccine. Key concerns relate to the lack of information about the genetic composition of the Candid #1 vaccine and limited knowledge regarding the viral genetic determinants of JUNV attenuation. RNA viruses, including Candid #1, replicate and perpetuate as quasi-species. Therefore, every amplification step to increase vaccine production may result in the appearance or enrichment within the virus population of genotypes within the potential of exhibiting increased virulence. As the genetic markers associated with Candid #1 attenuation are not clearly established, the emergence of potentially pathogenic variants within the Candid #1 population is difficult to assess. The potential genetic instability of Candid #1 is illustrated by the observation that Candid #1 isolates obtained from blood mononuclear cells of vaccinated rhesus monkeys showed a 1000 fold range of virulence, with some

isolates exhibiting up to ~100 fold higher virulence compared to the parental Candid #1 (Enria and Barrera Oro, 2002). Reverse genetic approaches could facilitate the development of a safer vaccine against AHF, and other HF arenaviral diseases, by facilitating the generation of molecular clones of genetically well-defined live-attenuated vaccine strains with the ability to induce strong protective immunity (Emonet et al., 2011).

The first use of reverse genetic approaches for arenavirus vaccine development involved the generation of an rLCMV where VSV G substituted for LCMV GPC. This rLCMV was highly attenuated but able to induce a strong protective immunity (Bergthaler et al., 2006). This finding led to examine the potential of LCMV as a viral vector system for immunization against non-LCMV antigens of interest. These studies showed that LCMV GPC could be replaced by a protein antigen of interest and the corresponding rLCMV, grown in cells expressing GPC, were able to induce good immune responses against the foreign protein while immunized mice remained free of disease symptoms (Fitz et al., 2010). However, the potential problem associated with pre-existing immunity against LCMV in human populations may limit the use of this system. Tri-segmented rLCMV able to stably express at high levels non-LCMV genes of interest have been found to exhibit attenuation *in vivo* while exhibiting sufficient levels of replication to induce strong protective immunity against a subsequent LCMV lethal challenge (Emonet et al., 2009). A similar strategy could be implemented to increase the safety Candid #1.

Among HF arenaviruses, LASV poses the main concern due to its vast endemic region and size of the population at risk. The geographic and socio-economic conditions intrinsic to the LASV endemic regions would pose significant difficulties for individuals at risk to have ready access to medical care, including antiviral drugs, to be treated against symptoms of LASV induced disease. Therefore, vaccination of the population at risk would be likely to provide a more effective strategy. However, a vaccination approach against LF similar to the one used against AHF is currently unfeasible because an attenuated strain for LASV has not been established. Nevertheless, a variety of approaches have been pursued aimed at the development of a LASV vaccine including DNA immunization approaches (Rodriguez-Carreno et al., 2005) and different vector-based vaccines. Recombinant vaccinia viruses expressing LASV NP or GP have been shown to provide cell-mediated immunity against LASV in guinea pigs and non-human primates (Fisher-Hoch et al., 2000). However, this approach would face the problem of the risk of using a vaccinia virus based vector in a population with high HIV prevalence. Alphavirus-based vectors have been used to induce protective immunity against LASV in guinea pigs (Pushko et al., 2001), and more recently a recombinant VSV where LASV GP substituted for the VSV G was shown to provide protection against a lethal challenge with LASV (Geisbert et al., 2005). Likewise, the alphavirus Venezuelan equine encephalitis virus (Lee et al., 2005), and the 17D Yellow fever vaccine (Bredenbeek et al., 2006) have shown promising results. Whether these recombinant vaccines provide long-term protection remains to be determined, an issue highly relevant in the case of LF due to a cumulative lifetime risk of exposure to LF vaccine within the West Africa human population. The induction of heterologous immunity by using a closely related but less pathogenic virus has been also explored for the development of a LASV vaccine. Thus, a reassortant (called ML29) between Mopeia, an OW arenavirus considered to be non-pathogenic to humans, and LASV has shown some promising results (Carrion et al., 2007), but detailed safety and efficacy studies have not been completed. An alternative approach for the development of a LF vaccine would be the use of reverse genetics to generate biologically contained versions of LASV in a similar way as described for Ebola virus (Halfmann et al., 2008) and influenza (Martinez-Sobrido and Garcia-Sastre, 2010). Recent work with LCMV has provided strong support for the feasibility of this approach (Fitz et al., 2010) to generate a safe and effective LASV vaccine. Likewise, the use of live-attenuated tri-segmented Candid #1

expressing relevant LASV T-cell epitopes could be used to induce protective immunity against JUNV and LASV.

Concluding remarks and perspectives

The development of reverse genetic systems for several arenaviruses has opened new research avenues to study basic aspects of the biology of this virus family, as well as the identification of viral determinants and mechanisms by which several arenaviruses cause HF disease in humans. Moreover, over the years the prototypic arenavirus LCMV has proven to be a superb model system to study virus–host interactions and associated disease. The ability to manipulate the LCMV genome and generate rLCMV with predetermined mutations would allow investigators to gain a detailed understanding of the roles played by the different viral genes in virus–host interactions resulting in very different phenotypic outcomes ranging from an acute and fatal meningitis to immunosuppression and chronic infections that although clinically silent can be associated with neurobehavioral abnormalities. On the other hand, the use of arenavirus MG cell-based assays, or single-cycle infectious arenaviruses, offers a number of benefits in the discovery and characterization of antiviral drugs against arenaviruses. These assays allow investigators to examine the effect of an antiviral drugs in the context of living cells, which facilitates the rapid identification of antiviral compounds with obvious undesirable cytotoxicity. In addition, because these assays do not involve the production of live virus, they overcome the difficulties posed by the need of BSL4 facilities to handle HF arenaviruses like LASV and JUNV. Likewise, the implementation of siRNA-based screens in the context of cell-based MG assays should facilitate the identification of host cell proteins that play key roles in arenavirus RNA replication and gene expression and thereby open potential for discovering novel targets that could be used in the development of effective anti-arenaviral drugs.

Acknowledgments

This is Publication Number 21050 from the Department of Immunology and Microbial Science, The Scripps Research Institute (TSRI), La Jolla, CA. This review presents data generated by many different laboratories. Because of space limitations we have relied extensively in recent reviews where more extensive detailed information, including all the original citations, can be found about the different topics and findings discussed in this minireview. Recognition and apologies are given in advance to the many colleagues whose original contributions have not been possible to cite. The research contributed by the authors of this minireview was supported by NIH grants RO1 AI047140, RO1 AI077719 and RO1 AI079665.

References

- Albarino, C.G., Bergeron, E., Erickson, B.R., Khristova, M.L., Rollin, P.E., Nichol, S.T., 2009. Efficient reverse genetics generation of infectious junin viruses differing in glycoprotein processing. *J. Virol.* 83 (11), 5606–5614.
- Barton, L.L., Mets, M.B., Beauchamp, C.L., 2002. Lymphocytic choriomeningitis virus: emerging fetal teratogen. *Am. J. Obstet. Gynecol.* 187 (6), 1715–1716.
- Bergthaler, A., Gerber, N.U., Merkler, D., Horvath, E., de la Torre, J.C., Pinschewer, D.D., 2006. Envelope exchange for the generation of live-attenuated arenavirus vaccines. *PLoS Pathog.* 2 (6), e51.
- Beyer, W.R., Popplau, D., Garten, W., von Laer, D., Lenz, O., 2003. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/SIP. *J. Virol.* 77 (5), 2866–2872.
- Blakqori, G., Weber, F., 2005. Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or lacking the nonstructural protein NSs. *J. Virol.* 79 (16), 10420–10428.
- Bolken, T.C., Laquerre, S., Zhang, Y., Bailey, T.R., Pevear, D.C., Kickner, S.S., Sperzel, L.E., Jones, K.F., Warren, T.K., Amanda Lund, S., Kirkwood-Watts, D.L., King, D.S., Shurtleff, A.C., Guttieri, M.C., Deng, Y., Bleam, M., Hruba, D.E., 2006. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. *Antiviral Res.* 69 (2), 86–97.

- Borden, K.L., Campbell Dwyer, E.J., Salvato, M.S., 1998a. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. *J. Virol.* 72 (1), 758–766.
- Borden, K.L., Campbelldwyer, E.J., Carille, G.W., Djavani, M., Salvato, M.S., 1998b. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. *J. Virol.* 72 (5), 3819–3826.
- Bredendbeek, P.J., Molenkamp, R., Spaan, W.J., Deubel, V., Marianneau, P., Salvato, M.S., Moshkoff, D., Zapata, J., Tikhonov, I., Patterson, J., Carrion, R., Ticer, A., Brasky, K., Lukashevich, I.S., 2006. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. *Virology* 345 (2), 299–304.
- Brunotte, L., Lelke, M., Hass, M., Kleinstueber, K., Becker-Ziaja, B., Gunther, S., 2011. Domain structure of Lassa virus L protein. *J. Virol.* 85 (1), 324–333.
- Buchmeier, M.J., Peters, C.J., de la Torre, J.C., 2007. *Arenaviridae: the Virus and Their Replication*, fifth ed. : Fields Virology, 2, pp. 1792–1827.
- Campbell Dwyer, E.J., Lai, H., MacDonald, R.C., Salvato, M.S., Borden, K.L., 2000. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. *J. Virol.* 74 (7), 3293–3300.
- Cao, W., Henry, M.D., Borrow, P., Yamada, H., Elder, J.H., Ravkov, E.V., Nichol, S.T., Compans, R.W., Campbell, K.P., Oldstone, M.B., 1998. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. *Science* 282 (5396), 2079–2081.
- Carlton, J., 2010. The ESCRT machinery: a cellular apparatus for sorting and scission. *Biochem. Soc. Trans.* 38 (6), 1397–1412.
- Carrion Jr., R., Patterson, J.L., Johnson, C., Gonzales, M., Moreira, C.R., Ticer, A., Brasky, K., Hubbard, G.B., Moshkoff, D., Zapata, J., Salvato, M.S., Lukashevich, I.S., 2007. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. *Vaccine* 25 (20), 4093–4102.
- Chen, M., Lan, S., Ou, R., Price, G.E., Jiang, H., de la Torre, J.C., Moskophidis, D., 2008. Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system. *J. Gen. Virol.* 89 (Pt 6), 1421–1433.
- Comai, L., 2004. Mechanism of RNA polymerase I transcription. *Adv. Protein Chem.* 67, 123–155.
- Cornu, T.I., de la Torre, J.C., 2001. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. *J. Virol.* 75 (19), 9415–9426.
- Cornu, T.I., de la Torre, J.C., 2002. Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. *J. Virol.* 76 (13), 6678–6688.
- Cornu, T.I., Feldmann, H., de la Torre, J.C., 2004. Cells expressing the RING finger Z protein are resistant to arenavirus infection. *J. Virol.* 78 (6), 2979–2983.
- Damonte, E.B., Coto, C.E., 2002. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. *Adv. Virus Res.* 58, 125–155.
- Djavani, M., Rodas, J., Lukashevich, I.S., Horejs, D., Pandolfi, P.P., Borden, K.L., Salvato, M.S., 2001. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. *J. Virol.* 75 (13), 6204–6208.
- Eckerle, L.D., Becker, M.M., Halpin, R.A., Li, K., Venter, E., Lu, X., Scherbakova, S., Graham, R.L., Baric, R.S., Stockwell, T.B., Spiro, D.J., Denison, M.R., 2010. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. *PLoS Pathog.* 6 (5), e1000896.
- Emonet, S.F., Garidou, L., McGavern, D.B., de la Torre, J.C., 2009. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. *Proc. Natl Acad. Sci. USA* 106 (9), 3473–3478.
- Emonet, S.F., Seregin, A.V., Yun, N.E., Poussard, A.L., Walker, A.G., de la Torre, J.C., Paessler, S., 2011. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and life-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. *J. Virol.* 85 (4), 1473–1483.
- Enria, D.A., Barrera Oro, J.G., 2002. Junin virus vaccines. *Curr. Top. Microbiol. Immunol.* 263, 239–261.
- Eschli, B., Quirin, K., Wepf, A., Weber, J., Zinkernagel, R., Hengartner, H., 2006. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. *J. Virol.* 80 (12), 5897–5907.
- Fearns, R., Peeples, M.E., Collins, P.L., 1997. Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. *Virology* 236 (1), 188–201.
- Fischer, S.A., Graham, M.B., Kuehnert, M.J., Kotton, C.N., Srinivasan, A., Marty, F.M., Comer, J.A., Guarner, J., Paddock, C.D., DeMeo, D.L., Shieh, W.J., Erickson, B.R., Bandy, U., DeMaria Jr., A., Davis, J.P., Delmonico, F.L., Pavlin, B., Likos, A., Vincent, M.J., Sealy, T.K., Goldsmith, C.S., Jernigan, D.B., Rollin, P.E., Packard, M.M., Patel, M., Rowland, C., Helfand, R.F., Nichol, S.T., Fishman, J.A., Ksiazek, T., Zaki, S.R., 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. *N. Engl. J. Med.* 354 (21), 2235–2249.
- Fisher-Hoch, S.P., Hutwagner, L., Brown, B., McCormick, J.B., 2000. Effective vaccine for lassa fever. *J. Virol.* 74 (15), 6777–6783.
- Flatz, L., Bergthaler, A., de la Torre, J.C., Pinschewer, D.D., 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. *Proc. Natl Acad. Sci. USA* 103 (12), 4663–4668.
- Flatz, L., Hegazy, A.N., Bergthaler, A., Verschoor, A., Claus, C., Fernandez, M., Gattinoni, L., Johnson, S., Kreppel, F., Kochanek, S., Broek, M., Radbruch, A., Levy, F., Lambert, P.H., Siegrist, C.A., Restifo, N.P., Lohning, M., Ochsenbein, A.F., Nabel, G.J., Pinschewer, D. D., 2010. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. *Nat. Med.* 16 (3), 339–345.
- Freder, E.O., 2002. Viral late domains. *J. Virol.* 76 (10), 4679–4687.
- Gallahr, W.R., DiSimone, C., Buchmeier, M.J., 2001. The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. *BMC Microbiol.* 1, 1.
- Garcin, D., Kolakofsky, D., 1990. A novel mechanism for the initiation of Tacaribe arenavirus genome replication. *J. Virol.* 64 (12), 6196–6203.
- Geisbert, T.W., Jones, S., Fritz, E.A., Shurtleff, A.C., Geisbert, J.B., Liebscher, R., Grolla, A., Stroher, U., Fernando, L., Daddario, K.M., Guttieri, M.C., Mothe, B.R., Larsen, T., Hensley, L.E., Jahrling, P.B., Feldmann, H., 2005. Development of a new vaccine for the prevention of Lassa fever. *PLoS Med.* 2 (6), e183.
- Groseth, A., Feldmann, H., Theriault, S., Mehmetoglu, G., Flick, R., 2005. RNA polymerase I-driven minigenome system for Ebola viruses. *J. Virol.* 79 (7), 4425–4433.
- Habjan, M., Penski, N., Spiegel, M., Weber, F., 2008. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. *J. Gen. Virol.* 89 (Pt 9), 2157–2166.
- Halfmann, P., Kim, J.H., Ebihara, H., Noda, T., Neumann, G., Feldmann, H., Kawaoka, Y., 2008. Generation of biologically contained Ebola viruses. *Proc. Natl Acad. Sci. USA* 105 (4), 1129–1133.
- Hass, M., Goliniz, U., Muller, S., Becker-Ziaja, B., Gunther, S., 2004. Replicon system for Lassa virus. *J. Virol.* 78 (24), 13793–13803.
- Hass, M., Lelke, M., Busch, C., Becker-Ziaja, B., Gunther, S., 2008. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. *J. Virol.* 82 (20), 10207–10217.
- Hass, M., Westerkofsky, M., Muller, S., Becker-Ziaja, B., Busch, C., Gunther, S., 2006. Mutational analysis of the lassa virus promoter. *J. Virol.* 80 (24), 12414–12419.
- Hawkins, J.L., Robbins, M.D., Warren, L.C., Xia, D., Petras, S.F., Valentine, J.J., Varghese, A. H., Wang, I.K., Subashii, T.A., Shelly, L.D., Hay, B.A., Landschulz, K.T., Geoghegan, K.F., Harwood Jr., H.J., 2008. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. *J. Pharmacol. Exp. Ther.* 326 (3), 801–808.
- Hay, B.A., Abrams, B., Zumbun, A.Y., Valentine, J.J., Warren, L.C., Petras, S.F., Shelly, L. D., Xia, A., Varghese, A.H., Hawkins, J.L., Van Camp, J.A., Robbins, M.D., Landschulz, K., Harwood Jr., H.J., 2007. Aminopyrrolidineamide inhibitors of site-1 protease. *Bioorg. Med. Chem. Lett.* 17 (16), 4411–4414.
- Hermann, T., 2000. Strategies for the design of drugs targeting RNA and RNA–protein complexes. *Angew. Chem. Int. Ed Engl.* 39 (11), 1890–1904.
- Hermann, T., Westhof, E., 2000. Rational drug design and high-throughput techniques for RNA targets. *Comb. Chem. High Throughput Screen.* 3 (3), 219–234.
- Isaacson, M., 2001. Viral hemorrhagic fever hazards for travelers in Africa. *Clin. Infect. Dis.* 33 (10), 1707–1712.
- Kawaoka, Y.E., 2004. Biology of negative strand RNA viruses: the power of reverse genetics. *Curr. Top. Microbiol. Immunol.* 283.
- Kranzusch, P.J., Schenk, A.D., Rahmeh, A.A., Radoshitzky, S.R., Bavari, S., Walz, T., Whelan, S.P., 2010. Assembly of a functional Machupo virus polymerase complex. *Proc. Natl Acad. Sci. USA* 107 (46), 20069–20074.
- Kunz, S., Borrow, P., Oldstone, M.B., 2002. Receptor structure, binding, and cell entry of arenaviruses. *Curr. Top. Microbiol. Immunol.* 262, 111–137.
- Kunz, S., Edelmann, K.H., de la Torre, J.C., Gorney, R., Oldstone, M.B., 2003. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. *Virology* 314 (1), 168–178.
- Kunz, S., Sevilla, N., Rojek, J.M., Oldstone, M.B., 2004. Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. *Virology* 325 (2), 432–445.
- Lan, S., Mclay Schelde, L., Wang, J., Kumar, N., Ly, H., Liang, Y., 2009. Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. *J. Virol.* 83 (13), 6357–6362.
- Lee, A.M., Rojek, J.M., Spiropoulou, C.F., Gundersen, A.T., Jin, W., Shaginian, A., York, J., Nunberg, J.H., Boger, D.L., Oldstone, M.B., Kunz, S., 2008. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. *J. Biol. Chem.* 283 (27), 18734–18742.
- Lee, J.S., Hadjipanayis, A.G., Parker, M.D., 2005. Viral vectors for use in the development of biodefense vaccines. *Adv. Drug Deliv. Rev.* 57 (9), 1293–1314.
- Lee, K.J., Novella, I.S., Teng, M.N., Oldstone, M.B., de la Torre, J.C., 2000. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. *J. Virol.* 74 (8), 3470–3477.
- Lelke, M., Brunotte, L., Busch, C., Gunther, S., 2010. An N-terminal region of Lassa virus L protein plays a critical role in transcription but not replication of the virus genome. *J. Virol.* 84 (4), 1934–1944.
- Lenz, O., ter Meulen, J., Klenk, H.D., Seidah, N.G., Garten, W., 2001. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. *Proc. Natl Acad. Sci. USA* 98 (22), 12701–12705.
- Liang, Y., Lan, S., Ly, H., 2009. Molecular determinants of Pichinde virus infection of guinea pigs—a small animal model system for arenaviral hemorrhagic fevers. *Ann. NY Acad. Sci.* 1171 (Suppl 1), E65–E74.
- Lopez, N., Jacamo, R., Franze-Fernandez, M.T., 2001. Transcription and RNA replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. *J. Virol.* 75 (24), 12241–12251.
- Lowen, A.C., Noonan, C., McLees, A., Elliott, R.M., 2004. Efficient bunyavirus rescue from cloned cDNA. *Virology* 330 (2), 493–500.
- Luytjes, W., Krystal, M., Enami, M., Parvin, J.D., Palese, P., 1989. Amplification, expression, and packaging of foreign gene by influenza virus. *Cell* 59 (6), 1107–1113.

- Maiztegui, J.I., McKee Jr., K.T., Barrera Oro, J.G., Harrison, L.H., Gibbs, P.H., Feuillade, M.R., Enria, D.A., Briggiler, A.M., Levis, S.C., Ambrosio, A.M., Halsey, N.A., Peters, C.J., 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. *AHF Study Group. J. Infect. Dis.* 177 (2), 277–283.
- Martinez-Sobrido, L., Emonet, S., Giannakas, P., Cubitt, B., Garcia-Sastre, A., de la Torre, J.C., 2009. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. *J. Virol.* 83 (21), 11330–11340.
- Martinez-Sobrido, L., Garcia-Sastre, A., 2010. Generation of recombinant influenza virus from plasmid DNA. *J. Vis. Exp.* 42.
- Martinez-Sobrido, L., Giannakas, P., Cubitt, B., Garcia-Sastre, A., de la Torre, J.C., 2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. *J. Virol.* 81 (22), 12696–12703.
- Martinez-Sobrido, L., Zuniga, E.I., Rosario, D., Garcia-Sastre, A., de la Torre, J.C., 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. *J. Virol.* 80 (18), 9192–9199.
- McKee Jr., K.T., Oro, J.G., Kuehne, A.I., Spisso, J.A., Mahlandt, B.G., 1992. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. *Intervirology* 34 (3), 154–163.
- Merkler, D., Horvath, E., Bruck, W., Zinkernagel, R.M., Del la Torre, J.C., Pinschewer, D.D., 2006. “Viral deja vu” elicits organ-specific immune disease independent of reactivity to self. *J. Clin. Invest.* 116 (5), 1254–1263.
- Meyer, B.J., Southern, P.J., 1994. Sequence heterogeneity in the termini of lymphocytic choriomeningitis virus genomic and antigenomic RNAs. *J. Virol.* 68 (11), 7659–7664.
- Morin, B., Coutard, B., Lelke, M., Ferron, F., Kerber, R., Jamal, S., Frangeul, A., Baronti, C., Charrel, R., de Lamballerie, X., Vonrhein, C., Lescar, J., Bricogne, G., Gunther, S., Canard, B., 2010. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. *PLoS Pathog.* 6 (9).
- Morita, E., Colf, L.A., Karren, M.A., Sandrin, V., Rodesch, C.K., Sundquist, W.I., 2010. Human ESCRT-III and VPS4 proteins are required for centrosome and spindle maintenance. *Proc. Natl Acad. Sci. USA* 107 (29), 12889–12894.
- Neuman, B.W., Adair, B.D., Burns, J.W., Milligan, R.A., Buchmeier, M.J., Yeager, M., 2005. Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. *J. Virol.* 79 (6), 3822–3830.
- Neumann, G., Kawaoka, Y., 2004. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. *Curr. Top. Microbiol. Immunol.* 283, 43–60.
- Ogawa, Y., Sugiura, K., Kato, K., Tohya, Y., Akashi, H., 2007. Rescue of Akabane virus (family Bunyaviridae) entirely from cloned cDNAs by using RNA polymerase I. *J. Gen. Virol.* 88 (Pt 12), 3385–3390.
- Oldstone, M.B., 2002. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. *Curr. Top. Microbiol. Immunol.* 263, 83–117.
- Palacios, G., Druce, J., Du, L., Tran, T., Birch, C., Briese, T., Conlan, S., Quan, P.L., Hui, J., Marshall, J., Simons, J.F., Egholm, M., Paddock, C.D., Shieh, W.J., Goldsmith, C.S., Zaki, S.R., Catton, M., Lipkin, W.I., 2008. A new arenavirus in a cluster of fatal transplant-associated diseases. *N. Engl. J. Med.* 358 (10), 991–998.
- Parker, W.B., 2005. Metabolism and antiviral activity of ribavirin. *Virus Res.* 107 (2), 165–171.
- Perez, M., Craven, R.C., de la Torre, J.C., 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. *Proc. Natl Acad. Sci. USA* 100 (22), 12978–12983.
- Perez, M., de la Torre, J.C., 2003. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. *J. Virol.* 77 (2), 1184–1194.
- Perez, M., Greenwald, D.L., de la Torre, J.C., 2004. Myristoylation of the RING finger Z protein is essential for arenavirus budding. *J. Virol.* 78 (20), 11443–11448.
- Peters, C.J., 2002. Human infection with arenaviruses in the Americas. *Curr. Top. Microbiol. Immunol.* 262, 65–74.
- Pinschewer, D.D., Perez, M., de la Torre, J.C., 2003a. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. *J. Virol.* 77 (6), 3882–3887.
- Pinschewer, D.D., Perez, M., de la Torre, J.C., 2005. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. *J. Virol.* 79 (7), 4519–4526.
- Pinschewer, D.D., Perez, M., Sanchez, A.B., de la Torre, J.C., 2003b. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. *Proc. Natl Acad. Sci. USA* 100 (13), 7895–7900.
- Pinschewer, D.D., Schedensack, M., Bergthaler, A., Horvath, E., Bruck, W., Lohning, M., Merkler, D., 2010. T cells can mediate viral clearance from ependyma but not from brain parenchyma in a major histocompatibility class I- and perforin-independent manner. *Brain* 133 (Pt 4), 1054–1066.
- Poch, O., Sauvaget, I., Delarue, M., Tordo, N., 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. *EMBO J.* 8 (12), 3867–3874.
- Pushko, P., Geisbert, J., Parker, M., Jahrling, P., Smith, J., 2001. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. *J. Virol.* 75 (23), 11677–11685.
- Qi, X., Lan, S., Wang, W., Schelde, L.M., Dong, H., Wallat, G.D., Ly, H., Liang, Y., Dong, C., 2010. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. *Nature* 468 (7325), 779–783.
- Racaniello, V.R., Baltimore, D., 1981. Cloned poliovirus complementary DNA is infectious in mammalian cells. *Science* 214 (4523), 916–919.
- Radoshitzky, S.R., Abraham, J., Spiropoulou, C.F., Kuhn, J.H., Nguyen, D., Li, W., Nagel, J., Schmidt, P.J., Nunberg, J.H., Andrews, N.C., Farzan, M., Choe, H., 2007. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. *Nature* 446 (7131), 92–96.
- Raju, R., Raju, L., Hacker, D., Garcin, D., Compans, R., Kolakofsky, D., 1990. Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. *Virology* 174 (1), 53–59.
- Rodriguez-Carreno, M.P., Nelson, M.S., Botten, J., Smith-Nixon, K., Buchmeier, M.J., Whitton, J.L., 2005. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. *Virology* 335 (1), 87–98.
- Rojek, J.M., Kunz, S., 2008. Cell entry by human pathogenic arenaviruses. *Cell. Microbiol.* 10 (4), 828–835.
- Rojek, J.M., Lee, A.M., Nguyen, N., Spiropoulou, C.F., Kunz, S., 2008. Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. *J. Virol.* 82 (12), 6045–6051.
- Rojek, J.M., Pasqual, G., Sanchez, A.B., Nguyen, N.T., de la Torre, J.C., Kunz, S., 2010. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. *J. Virol.* 84 (1), 573–584.
- Sakai, J., Nohturfft, A., Goldstein, J.L., Brown, M.S., 1998. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. *J. Biol. Chem.* 273 (10), 5785–5793.
- Sanchez, A.B., de la Torre, J.C., 2005. Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus. *J. Virol.* 79 (11), 7262–7268.
- Sanchez, A.B., de la Torre, J.C., 2006. Rescue of the prototypic Arenavirus LCMV entirely from plasmid. *Virology* 350 (2), 370–380.
- Saunders, A.A., Ting, J.P., Meisner, J., Neuman, B.W., Perez, M., de la Torre, J.C., Buchmeier, M.J., 2007. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. *J. Virol.* 81 (11), 5649–5657.
- Schneider, U., Schwemmle, M., Staeheli, P., 2005. Genome trimming: a unique strategy for replication control employed by Borna disease virus. *Proc. Natl Acad. Sci. USA* 102 (9), 3441–3446.
- Seidah, N.G., Khatib, A.M., Prat, A., 2006. The proprotein convertases and their implication in sterol and/or lipid metabolism. *Biol. Chem.* 387 (7), 871–877.
- Sousa, R., Mukherjee, S., 2003. T7 RNA polymerase. *Prog. Nucleic Acid Res. Mol. Biol.* 73, 1–41.
- Strecker, T., Eichler, R., Meulen, J., Weissenhorn, W., Dieter Klenk, H., Garten, W., Lenz, O., 2003. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. *J. Virol.* 77 (19), 10700–10705.
- Strecker, T., Maisa, A., Daffis, S., Eichler, R., Lenz, O., Garten, W., 2006. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. *J. Virol.* 3, 93.
- Subbarao, K., Katz, J.M., 2004. Influenza vaccines generated by reverse genetics. *Curr. Top. Microbiol. Immunol.* 283, 313–342.
- Suheck, S.J., Greenberg, W.A., Tolbert, T.J., Wong, C.H., 2000. Design of small molecules that recognize RNA: development of aminoglycosides as potential antitumor agents that target oncogenic RNA sequences. *Angew. Chem. Int. Ed Engl.* 39 (6), 1080–1084.
- Suheck, S.J., Wong, C.H., 2000. RNA as a target for small molecules. *Curr. Opin. Chem. Biol.* 4 (6), 678–686.
- Taniguchi, T., Palmieri, M., Weissmann, C., 1978. QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. *Nature* 274 (5668), 223–228.
- Tortorici, M.A., Albarino, C.G., Posik, D.M., Ghiringhelli, P.D., Lozano, M.E., Rivera Pomar, R., Romanowski, V., 2001. Arenavirus nucleocapsid protein displays a transcriptional antitermination activity in vivo. *Virus Res.* 73 (1), 41–55.
- Urata, S., Noda, T., Kawaoka, Y., Yokosawa, H., Yasuda, J., 2006. Cellular factors required for Lassa virus budding. *J. Virol.* 80 (8), 4191–4195.
- Urata, S., Yun, N., Pasquato, A., Paessler, S., Kunz, S., de la Torre, J.C., 2011. Antiviral activity of a small molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. *J. Virol.* 85 (2), 795–803.
- Vieth, S., Torda, A.E., Asper, M., Schmitz, H., Gunther, S., 2004. Sequence analysis of L RNA of Lassa virus. *Virology* 318 (1), 153–168.
- Volpon, L., Osborne, M.J., Capul, A.A., de la Torre, J.C., Borden, K.L., 2010. Structural characterization of the Z RING–eIF4E complex reveals a distinct mode of control for eIF4E. *Proc. Natl Acad. Sci. USA* 107 (12), 5441–5446.
- von Messling, V., Cattaneo, R., 2004. Toward novel vaccines and therapies based on negative-strand RNA viruses. *Curr. Top. Microbiol. Immunol.* 283, 281–312.
- Wang, S., Huber, P.W., Cui, M., Czarnik, A.W., Mei, H.Y., 1998. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. *Biochemistry* 37 (16), 5549–5557.
- Wang, Y., Hamasaki, K., Rando, R.R., 1997. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. *Biochemistry* 36 (4), 768–779.
- Wilson, W.D., Li, K., 2000. Targeting RNA with small molecules. *Curr. Med. Chem.* 7 (1), 73–98.
- York, J., Nunberg, J.H., 2006. Role of the stable signal peptide of Junin arenavirus envelope glycoprotein in pH-dependent membrane fusion. *J. Virol.* 80 (15), 7775–7780.
- York, J., Romanowski, V., Lu, M., Nunberg, J.H., 2004. The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1–G2 complex. *J. Virol.* 78 (19), 10783–10792.
- Zinkernagel, R.M., 2002. Lymphocytic choriomeningitis virus and immunology. *Curr. Top. Microbiol. Immunol.* 263, 1–5.